The anticancer efficiency of the xenogeneic vaccine and the indication for its use
Aim: To investigate the anticancer efficiency of the xenogeneic vaccine in different tumor models and to assess the possibility whether level of antibodies (Ab) specific for vaccine’s proteins can be used as an indication for its use. Methods: Mice with Lewis lung carcinoma (LLC), Ehrlich carcinoma...
Saved in:
| Published in: | Experimental Oncology |
|---|---|
| Date: | 2014 |
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2014
|
| Subjects: | |
| Online Access: | https://nasplib.isofts.kiev.ua/handle/123456789/145335 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Journal Title: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Cite this: | The anticancer efficiency of the xenogeneic vaccine and the indication for its use / T.V. Symchych, N.I. Fedosova, O.M. Karaman, L.M. Yevstratieva, H.S. Lisovenko, I.M. Voyeykova, H.P. Potebnia // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 79-84. — Бібліогр.: 33 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862663839379619840 |
|---|---|
| author | Symchych, T.V. Fedosova, N.I. Karaman, O.M. Yevstratieva, L.M. Lisovenko, H.S. Voyeykova, I.M. Potebnia, H.P. |
| author_facet | Symchych, T.V. Fedosova, N.I. Karaman, O.M. Yevstratieva, L.M. Lisovenko, H.S. Voyeykova, I.M. Potebnia, H.P. |
| citation_txt | The anticancer efficiency of the xenogeneic vaccine and the indication for its use / T.V. Symchych, N.I. Fedosova, O.M. Karaman, L.M. Yevstratieva, H.S. Lisovenko, I.M. Voyeykova, H.P. Potebnia // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 79-84. — Бібліогр.: 33 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | Aim: To investigate the anticancer efficiency of the xenogeneic vaccine in different tumor models and to assess the possibility whether level of antibodies (Ab) specific for vaccine’s proteins can be used as an indication for its use. Methods: Mice with Lewis lung carcinoma (LLC), Ehrlich carcinoma (EC) or Sarcoma 37 (S37) were immunized with a xenogeneic anticancer vaccine based on chicken embryo proteins (CEP) and its anticancer activity was examined. The level of specific Ab in the blood serum of non-immunized tumor-bearing mice was studied by ELISA. Results: CEP application statically significantly inhibited the growth of LLC (the index of tumor growth inhibition was 42.10–53.13% depending on the day of tumor growth); vaccinated mice with EC showed significant tumor growth inhibition and life prolongation by 34.48%. Among mice with S37, there was noticed no antitumor effect. The number of tumor-bearing non-immunized mice which have had pre-existing CEP-specific Ab did not differ depending on the tumor model. The level of CEP-specific Ab among mice with LLC and EC increased with the growth of the tumor volume, but it decreased among mice bearing S37. Probably, the low level of CEP-specific Ab alongside huge tumor burden shows it is futile to apply the CEP-based vaccine. Conclusion: Different tumor strains vary in their susceptibility to CEP-based vaccine. Probably, the low level of CEP-specific Ab when a tumor burden is huge shows it is futile to apply the CEP-based vaccine. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies.
|
| first_indexed | 2025-12-07T15:12:54Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-145335 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-12-07T15:12:54Z |
| publishDate | 2014 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Symchych, T.V. Fedosova, N.I. Karaman, O.M. Yevstratieva, L.M. Lisovenko, H.S. Voyeykova, I.M. Potebnia, H.P. 2019-01-20T16:33:56Z 2019-01-20T16:33:56Z 2014 The anticancer efficiency of the xenogeneic vaccine and the indication for its use / T.V. Symchych, N.I. Fedosova, O.M. Karaman, L.M. Yevstratieva, H.S. Lisovenko, I.M. Voyeykova, H.P. Potebnia // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 79-84. — Бібліогр.: 33 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/145335 Aim: To investigate the anticancer efficiency of the xenogeneic vaccine in different tumor models and to assess the possibility whether level of antibodies (Ab) specific for vaccine’s proteins can be used as an indication for its use. Methods: Mice with Lewis lung carcinoma (LLC), Ehrlich carcinoma (EC) or Sarcoma 37 (S37) were immunized with a xenogeneic anticancer vaccine based on chicken embryo proteins (CEP) and its anticancer activity was examined. The level of specific Ab in the blood serum of non-immunized tumor-bearing mice was studied by ELISA. Results: CEP application statically significantly inhibited the growth of LLC (the index of tumor growth inhibition was 42.10–53.13% depending on the day of tumor growth); vaccinated mice with EC showed significant tumor growth inhibition and life prolongation by 34.48%. Among mice with S37, there was noticed no antitumor effect. The number of tumor-bearing non-immunized mice which have had pre-existing CEP-specific Ab did not differ depending on the tumor model. The level of CEP-specific Ab among mice with LLC and EC increased with the growth of the tumor volume, but it decreased among mice bearing S37. Probably, the low level of CEP-specific Ab alongside huge tumor burden shows it is futile to apply the CEP-based vaccine. Conclusion: Different tumor strains vary in their susceptibility to CEP-based vaccine. Probably, the low level of CEP-specific Ab when a tumor burden is huge shows it is futile to apply the CEP-based vaccine. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Original contributions The anticancer efficiency of the xenogeneic vaccine and the indication for its use Article published earlier |
| spellingShingle | The anticancer efficiency of the xenogeneic vaccine and the indication for its use Symchych, T.V. Fedosova, N.I. Karaman, O.M. Yevstratieva, L.M. Lisovenko, H.S. Voyeykova, I.M. Potebnia, H.P. Original contributions |
| title | The anticancer efficiency of the xenogeneic vaccine and the indication for its use |
| title_full | The anticancer efficiency of the xenogeneic vaccine and the indication for its use |
| title_fullStr | The anticancer efficiency of the xenogeneic vaccine and the indication for its use |
| title_full_unstemmed | The anticancer efficiency of the xenogeneic vaccine and the indication for its use |
| title_short | The anticancer efficiency of the xenogeneic vaccine and the indication for its use |
| title_sort | anticancer efficiency of the xenogeneic vaccine and the indication for its use |
| topic | Original contributions |
| topic_facet | Original contributions |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/145335 |
| work_keys_str_mv | AT symchychtv theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT fedosovani theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT karamanom theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT yevstratievalm theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT lisovenkohs theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT voyeykovaim theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT potebniahp theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT symchychtv anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT fedosovani anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT karamanom anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT yevstratievalm anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT lisovenkohs anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT voyeykovaim anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse AT potebniahp anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse |